IBD

Entyvio vs Remicade compares the two drugs that target the tumor necrosis factor pathway. Entyvio is the brand name of Vedolizumab and is indicated primarily for the treatment of Crohn’s disease and ulcerative colitis. Remicade is infliximab indicated for autoimmune rheumatic conditions. Remicade is a chimeric monoclonal IgG1 antibody that inhibits TNF-α, which is the … Read more